WHAT IS CLAIMED IS:

15

- 1. A method for preventing the incidence of diabetes mellitus in a subject with chronic heart failure comprising the administration of a therapeutically effective amount of an ACE inhibitor.
- 2. A method as defined in claim 1, wherein said subject has impaired fasting plasma glucose (FMG).
- 3. A method as defined in claim 1, wherein said chronic heart failure is a result of symptomatic or asymptomatic left ventricular systolic dysfunction.
 - 4. A method as defined in claim 3, wherein said chronic heart failure is a result of symptomatic left ventricular systolic dysfunction.
 - 5. A method as defined in claim 1, wherein said ACE inhibitor is selected from the group consisting of: enalapril (vasotec), captopril (capoten), lisinopril (prinivil, zestril), quinapril (accupril) and ramapril (altace).
- 20 6. A method as defined in claim 5, wherein said ACE inhibitor is administered in a dosage of about 5-20 mg/day.
 - 7. A method as defined in claim 6, wherein said ACE inhibitor is enalapril.
- 8. A method for preventing the incidence of diabetes mellitus in a subject with chronic heart failure that is being treated with a β-blocker comprising the administration of a therapeutically effective amount of an ACE inhibitor.
- 9. A method as defined in claim 8, wherein said subject has impaired fasting plasma30 glucose (FMG).
 - 10. A method as defined in claim 8, wherein said chronic heart failure is a result of

symptomatic or asymptomatic left ventricular systolic dysfunction.

11. A method as defined in claim 10, wherein said chronic heart failure is a result of symptomatic left ventricular systolic dysfunction.

5

- 12. A method as defined in claim 8, wherein said ACE inhibitor is selected from the group consisting of: enalapril (vasotec), captopril (capoten), lisinopril (prinivil, zestril), quinapril (accupril) and ramapril (altace).
- 13. A method as defined in claim 12, wherein said ACE inhibitor is administered in a dosage of about 5-20 mg/day.
 - 14. A method as defined in claim 13, wherein said ACE inhibitor is enalapril.
- 15. A method as described in claim 14, wherein said β-blocker is metoprolol.
 - 16. A method for preventing the incidence of diabetes mellitus in a subject with chronic heart failure comprising the administration of a therapeutically effective amount of angiotensin II receptor antagonist.

20

- 17. A method as defined in claim 16, wherein said subject has impaired fasting plasma glucose (FMG).
- 18. A method as defined in claim 16, wherein said chronic heart failure is a result ofsymptomatic or asymptomatic left ventricular systolic dysfunction.
 - 19. A method as defined in claim 18, wherein said chronic heart failure is a result of symptomatic left ventricular systolic dysfunction.
- 20. A method as defined in claim 16, wherein said angiotensin II receptor antagonist is selected from the group consisting of: losartan (cozaar), candesartan (atacand), irbesartan (avapro), telmisartan (micardis) and valsartan (diovan).

- 21. A method as defined in claim 20, wherein said angiotensin II receptor antagonist is administered in a dosage of about 5-20 mg/day.
- 5 22. A method as defined in claim 21, wherein said ACE inhibitor is losartan.